Sosei Group Corporation (SOLTF) fair value: what the stock is really worth
We calculate from audited financials what Sosei Group Corporation is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Sep 23, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Sosei Group Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $4.91 – $59.26 · fair‑value band $3.78 – $7.16 · the $8.35 price screens above the $5.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Sosei Group in your weekly email
Every Wednesday you see whether Sosei Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally.
Show more
Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychiatric disorders; ORX750, an OX2 agonist for narcolepsy, idiopathic hypersomnia, and other sleep-wake disorders; NBI-1117570, a dual muscarinic M1/M4 agonist; and HTL0039732, an EP4 antagonist immunotherapy drug. The company's products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; and NXE0048149, a GPR52 agonist for schizophrenia. Its products in preclinical trial comprise KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. The company also develops other discovery-stage drugs. It has strategic collaborations with Tempero Bio, Pharmenable Therapeutics, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Lilly, AbbVie, Genentech, Pfizer, Neurocrine Biosciences, Antiverse, and Novartis International AG. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato, Japan.
Stock analysis
Sosei Group Corporation (SOLTF) currently trades at $8.35, while our model-based Fair Value estimate is $5.73, implying the stock looks roughly 45.7% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $3.78 (bear) to $7.16 (bull), the price of $8.35 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sosei Group Corporation reported revenue of ¥29.6B in FY2025 versus ¥17.7B in FY2021, a compound +13.7%/yr. Reported net income was −¥12.5B in FY2025.
Key figures
Market cap $753M · EPS (TTM) $−0.8600 · Net margin −42.3% · Return on equity −15.3% · Return on assets (EBIT) −1.7% · Operating margin 28.8% · Revenue (TTM) ¥34.2B · Revenue growth (YoY) +69.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades at its 52-week high and 70% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −31%, SOLTF screens richer than that median.
Fair Value models
Bear $3.78Fair Value $5.73Bull $7.16
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.4%
Start year 2020 (pandemic). Over 10 years: +13.8% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
10.5% (2020) → −27.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Sosei Group Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−31% · Above median
Profitability
Return on assets−1% · Above median
Net margin (TTM)−29% · Below median
Operating margin (TTM)29% · Top 25%
Growth and dividend
Revenue growth69% · Top 25%
Balance sheet
Debt / equity0.77× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/S (TTM)0.02× · Cheapest 25%
EV/EBITDA20.3× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)61· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sosei Group Corporation Fair Value". https://www.fairvalue-calculator.com/stock/SOLTF
Frequently asked questions
Is Sosei Group Corporation (SOLTF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $5.73 versus a price of $8.35, about −31% upside (overvalued).
What is the fair value of SOLTF?
Our model-based fair value for Sosei Group Corporation is $5.73 (as of Sep 23, 2026), built from audited fundamentals. The current price: $8.35.
What is the quality score of SOLTF?
Sosei Group Corporation has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sosei Group Corporation (SOLTF)?
Our model-based price target is the fair value of $5.73 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $3.78, optimistic scenario $7.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Sosei Group Corporation stock forecast for 2026?
Our models put fair value at $5.73, about −31% upside versus a price of $8.35 (overvalued). Cautious scenario $3.78, optimistic scenario $7.16. The calculation is refreshed regularly with new filings.
What is the revenue of Sosei Group Corporation (SOLTF)?
Sosei Group Corporation reported trailing-twelve-month revenue of about ¥34.2B (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Sosei Group Corporation (SOLTF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sosei Group Corporation it is $5.73 per share (as of Sep 23, 2026), against a price of $8.35. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sosei Group Corporation stock overvalued or undervalued in 2026?
As of Sep 23, 2026, SOLTF trades above its calculated fair value: price $8.35, fair value $5.73, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SOLTF?
No. The price is what the market pays today ($8.35); the fair value is what the company's own numbers justify ($5.73). For Sosei Group Corporation the two are $2.62 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sosei Group Corporation worth?
The market values Sosei Group Corporation at about $753M (market capitalisation, as of Sep 23, 2026). Per share that is $8.35; our models calculate a fair value of $5.73 per share.
What do the bullish and bearish scenarios say about SOLTF?
Our models span a range for Sosei Group Corporation: cautious scenario $3.78, base $5.73, optimistic $7.16 per share (as of Sep 23, 2026, price $8.35). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sosei Group Corporation (SOLTF)?
Balance-sheet figures for Sosei Group Corporation (as of Sep 23, 2026): return on equity −15.3%, debt of 0.77 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is SOLTF from its 52-week high?
Sosei Group Corporation trades at $8.35, at its 52-week high of $8.35 and 70% above the low of $4.91 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of $5.73 is for.
Which stocks are comparable to Sosei Group Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sosei Group Corporation stock attractive at the current price?
The data as of Sep 23, 2026: price $8.35, calculated fair value $5.73 (−31%), Quality Score 34/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SOLTF calculated?
We run Sosei Group Corporation through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $5.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Sosei Group Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sosei Group Corporation (SOLTF)?
The closing price on Sep 22, 2026 was $8.35. Our model-based fair value is $5.73, about −31% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sosei Group Corporation right now?
The price sits above even our optimistic bull case ($7.16). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($3.78 to $7.16) leaves room in how you read the outcome.
Key figures of Sosei Group Corporation
How large is the market capitalisation of Sosei Group Corporation (SOLTF)?
The market capitalisation of Sosei Group Corporation is $753M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Sosei Group Corporation (SOLTF)?
Earnings per share at Sosei Group Corporation are $−0.8600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sosei Group Corporation (SOLTF)?
The net margin of Sosei Group Corporation is −42.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sosei Group Corporation (SOLTF)?
The return on equity (ROE) of Sosei Group Corporation is −15.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sosei Group Corporation (SOLTF)?
On an EBIT basis the return on assets of Sosei Group Corporation is −1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sosei Group Corporation (SOLTF)?
The operating margin of Sosei Group Corporation is 28.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sosei Group Corporation (SOLTF)?
Revenue at Sosei Group Corporation is growing +69.4% versus a year earlier (3y avg +23.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sosei Group Corporation (SOLTF)?
Earnings per share at Sosei Group Corporation are growing +27.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sosei Group Corporation (SOLTF) generate?
The free cash flow of Sosei Group Corporation is −¥3.1B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sosei Group Corporation (SOLTF) carry?
The net debt of Sosei Group Corporation is ¥37.0B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sosei Group Corporation in the live analysis
One click puts Sosei Group Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026